

November 15, 2021

CLINICAL STUDY

EudraCT number: 2011-004815-22

Sponsor code: INDICES/WP2/01

Title: Individualized drug therapy based on pharmacogenomics: focus on carboxylesterase 1 (CES1)

The interdisciplinary project INDICES had as one of its main objectives to improve the treatment with drugs metabolized by the liver enzyme carboxylesterase 1 (CES1) based on the combination of genetics, metabolomics, pharmacology, and clinical science. INDICES included a clinical study with administration of a low dose of methylphenidate as a pharmacological probe for monitoring of the liver activity of CES1 in young healthy human subjects followed by correlation of this activity to variation in the gene encoding CES1. Since this study does not qualify as “clinical trial” according to the definition used in “Commission Guideline — Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/200” and registration of the study as a “clinical trial” in EudraCT was not required, its results were not posted.



Dr. Henrik Berg Rasmussen

Principal Scientist,
Institute of Biological Psychiatry,
Psychiatric Services of the Capital Region of Denmark